In the complex landscape of drug development, having a reliable and trusted partner can make all the difference. Discover how Svar Life Science CRO partners with Alentis Therapeutics to help drive their groundbreaking advancements in oncology and fibrosis treatments.
Since 2020 Svar Life Science CRO has been working with Alentis Therapeutics, a Swiss biotech company known for groundbreaking work in oncology and fibrosis, supporting their work in the development of anti-Claudin-1 (CLDN1) therapies.
Over the course of more than 40 studies, the role of Svar has extended beyond mere execution, acting as a trusted collaborator, supporting Alentis in navigating complex immunogenicity, pharmacokinetic, and biomarker studies with precision and speed, ultimately helping inform critical strategic decision.
Download the full article to know how Svar supports Alentis’ progress.